Hoth Therapeutics Inc. Common Stock (HOTH)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable competitive advantages, conservative finances, and a margin of safety. Hoth Therapeutics is a clinical-stage biopharmaceutical company with two employees, developing HT-001 for rash and skin disorders, plus HT-KIT and HT-TBI. That is a research-stage pipeline, not a proven business with a moat. The supplied data show revenue growth is N/A, and the only profit-growth figure is 22.54% without a named filed period, so I cannot treat it as a dependable trajectory. The balance sheet has no debt, shown by a debt-to-equity ratio of 0.00, which is a modest positive. But the economics are poor: trailing free cash flow is -$10.1 million, a negative FCF yield of -67.9% against a $14.8 million market cap. As of the 2026-07-17 close, the price is $0.82, with a P/E of -0.91 and P/B of 2.05. FairStock calculations show ROE of -191.40%, ROCE of -100.89%, a Piotroski F-Score of 0/9, and an Altman Z-Score of -11.97, all pointing to severe weakness and distress risk. The 52-week range of $0.49 to $2.45 shows violent price swings, while beta of 0.58 is relatively low. The computed Lynch category is none, because only zero years of filed annual results exist and three are needed. At $0.82, the stock may look cheap, but without earnings, cash flow, or a proven moat, there is no margin of safety in the Graham sense. I would need evidence of clinical progress and a credible path to cash generation before the numbers could qualify as investment-grade.

In plain English: Hoth Therapeutics is a very small healthcare company trying to develop treatments for skin rashes and other conditions. It has only two employees, no product revenue shown, and it is losing money, so the business looks weak financially. At $0.82, the price may seem low, but against its losses and cash use, it looks expensive rather than cheap; a simple quality score from the data is 26 out of 100.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-07-17 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer